Captor Therapeutics®

H1 2023 update

Corporate Presentation

September 2023

All images by Piotr Piatek

Legal notice

This document and the information contained herein (unless otherwise indicated) have been prepared by Captor Therapeutics S.A. (the “Issuer”) solely for informational purposes. For this notice, the presentation that follows shall mean and include the slides that follow, the oral presentation of the slides by the Issuer or any person on behalf of the Issuer, any question-and-answer session that follows the oral presentation, hard copies of this document, and any materials distributed at, or in connection with the presentation (collectively, the “Presentation”). By attending the meeting at which the Presentation is made, or by reading the Presentation, you will be deemed to have (i) agreed to all of the following restrictions and made the following undertakings and (ii) acknowledged that you understand the legal and regulatory sanctions attached to the misuse, disclosure or improper circulation of the Presentation.

The information contained in this Presentation may not be reproduced or redistributed in any way, in whole or in part, to any other person without the prior written consent of the Issuer. This Presentation does not purport to contain all the information that may be required by the recipient to assess the Issuer or its securities. The Issuer prepared this Presentation based on the information which it has and from sources believed to be reliable. To the extent available, the industry, market, and competitive position data contained in this Presentation come from official or third-party sources. There is no guarantee of the accuracy or completeness of such data.

This Presentation contains neither a complete nor a comprehensive financial or commercial analysis of the Issuer, nor does it present its position or prospects in a complete or comprehensive manner. The Issuer has prepared the Presentation with due care, however certain inconsistencies or omissions might have appeared in it. Therefore it is recommended that any person who intends to undertake any investment decision regarding any security issued by the Issuer shall only rely on information released as an official communication (i.e., current/periodic reports) in accordance with the legal and regulatory provisions.

This Presentation may contain certain forward-looking statements, forecasts, estimates, projections, and opinions ("Forward-looking Statements"). By their nature, Forward-looking Statements involve known and unknown risks, uncertainties, assumptions, and other factors because they relate to events and depend on circumstances that will occur in the future whether or not outside the control of the Issuer. No representation is made or will be made that any Forward-looking Statements will be achieved or will prove to be correct. Actual future results and operations could vary materially from the Forward-looking Statements. Similarly, no representation is given that the assumptions disclosed in this Presentation upon which Forward-looking Statements may be based are reasonable. The recipient acknowledges that circumstances may change and the contents of this Presentation may become outdated as a result. The assumptions included herein do not constitute profit forecasts or profit estimates.

No warranties or representations can be made as to the comprehensiveness or reliability of the information contained in this Presentation. Neither the Issuer nor its directors, managers, advisers or representatives of such persons shall bear any liability that might arise in connection with any use of this Presentation. Furthermore, no information contained herein constitutes an obligation or representation of the Issuer, its managers or directors, its shareholders, subsidiary undertakings, advisers or representatives of such persons.
Data contained in this Presentation is valid as of the day of its preparation. Consequently, this Presentation will not be subject to changes, updates or modifications to account for events which might occur after this day.

This Presentation does not constitute or form part of, and should not be construed as, an offer to sell or issue, or the solicitation of an offer to purchase, subscribe to, or acquire the Issuer or the Issuer´s securities, or an inducement to enter into investment activity in any jurisdiction in which such offer, solicitation, inducement or sale would be unlawful before registration, exemption from registration or qualification under the securities laws of such jurisdiction. No part of this Presentation, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. This presentation is not for publication, release, or distribution in any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction nor should it be taken or transmitted into such jurisdiction.

Captor Therapeutics®

CORPORATE SUMMARY

Captor Therapeutics – key take-aways in H1 2023

Corporate

- ✓ Announcement of the **next steps in the Strategy** - increase of authorised share capital
- ✓ **Strengthening** of the scientific and business team
- ✓ Cooperation with **international advisors**: Wedbush and M.S.Q Ventures
- ✓ **Collaboration with Ono** has started well with excellent cooperation between the companies and an improvement in cash flow for Captor
- ✓ Several pharma companies enter into **Confidentiality Agreements** to look at Captor projects

R&D

- ✓ **Target announcements** in CT-01, CT-02 and CT-05
- ✓ **Key R&D Announcements**:
  - ✓ **CT-01**
    Completed in-life part of GLP-tox – no gross findings
  - ✓ **CT-02**
    Partnering discussions initiated
  - ✓ **CT-03:**
    MTD and DRF in monkeys completed; no heart related issues in supraefficacious concentrations
  - ✓ **CT-05:**
    Partnering discussions initiated

Optigrade™ discovery platform

- ✓ New E3 Ligases - degradation confirmed for **two new kinases (PTK2b and Wee1)**
- ✓ New project: **CT-09 targeting intrinsically-disordered protein in oncology**

PLN 38,2 M incurred for R&D

Cash flow supported by non-dilutive grant funding which helps preserve capital in these difficult market conditions.

Company started a new research project, co-financed with **PLN 52.2 million by the Medical Research Agency (ABM),** related to the development of an anti-cancer therapy for the treatment of patients with colorectal cancer and other types of cancer.

The company has obtained shareholders' consent for introduction of authorized share capital and issue shares on this basis, which will take place at the most favorable time for it.

Captor Therapeutics®

Roadmap to our strategic objectives

Fully-owned portfolio of owned clinical and preclinical assets, while sharing development or commercial risks with partners at the optimum time for each asset.

4 active pipeline projects*

Clinical trials in patients of 2 lead pipeline assets – CT-01 and CT-03

Further preclinical work on CT-02 and CT-05, with partnering or licensing at preclinical stage

Optigrade™ Platform

2 new collaborative areas – Novel ligases and ADCs
Leverage our platform for additional non-dilutive funding and validation
Source of new early pipeline projects

Nurix – Seagen deal for DACs – Degrader-Antibody Conjugates

** As was announced last year, the NCBR grant funding for the CT-04 project came to an end. Although this project remains high potential, after considering multiple factors including the early stage of development, the financial and other resources required for progress, and the prospects of the other internal projects CT-01, CT-03, CT-02 and CT-05, it was decided to focus on the development of the other projects*

Captor Therapeutics®

Significant strengthening of the team

Donald Coppen
Business Development Director

- PhD Southampton University
- MBA Cranfield University
- Over 20 years experience in Business Development & Alliance Management

Andrew Saunders
Chief Medical Officer

- MD Trinity College Dublin
- Over 20 years of experience in conducting clinical trials
- Past experience in hemato-oncology and solid tumours

Tomas Drmota
VP Early Discovery

- Ph.D. Charles Univ. Prague
- Post-doc Univ. of Glasgow GPCRs research
- 15 years AstraZeneca drug discovery/development projects leadership
- Program manager SOTIO biologicals-cell therapy

EDUCATION

PREVIOUS EXPERIENCE

International financial advisors

- Exclusive strategic financial advisor
- Identification and evaluation of potential strategic opportunities:
  - licensing or partnering transaction
  - asset transaction
  - strategic transaction regarding shares or assets
- Maximizing value for the Company's shareholders
- Long-term cooperation

- Specialist healthcare business development broker focused on Greater China
- Objective is to establish potential partnerships in Greater China area (China, Taiwan, Hong-Kong, Macau)
- In 2023 MSQ an advisor to C4 Therapeutics by the licensing agreement in Greater China with Betta Pharmaceuticals - $10M upfront/ $25M equity investment/ up to $357M in milestones

Ono Pharmaceutical - a strong partner for Captor

Worldwide drug discovery collaboration with Ono Pharmaceutical to develop novel small molecule degrader drugs against a currently undrugged target of interest in neurodegenerative diseases.

R&D Capabilities Combining In-house Drug Discovery and Open Innovation

Number of joint research projects with universities, biopharmaceutical companies, etc.
(As of end of March 2022)
About **200**

Number of approvals obtained
(FY2021)
7 approvals

A Pipeline that Continuously Markets New Drugs



Number of clinical trials conducted
(FY2021)
82 trials

Number of new products launched and additional indications approved
(FY2017 to FY2021)
31 products

Continuing Vigorous Investment in Drug Development

R&D costs
(FY2021)
¥75.9 billion

R&D cost-to-revenue ratio
(FY2021)
21.0 %

Other ONO partnerships

Bristol Myers Squibb, Pfizer, HELSINN, Bial, SK, SERVIER, GILEAD, Tibon therapeutics, AMGEN

Payment of remuneration to the Company:

- Fee upon signature of the collaboration agreement
- Ono pays all research costs of Captor
- Milestones payments as products progress

This collaboration shows that Captor's Optigrade™ TPD platform is attractive for international pharma partners as well as allowing the Company to enter a new disease area at minimal cost.

Captor Therapeutics®

DEVELOPMENT OF PROJECTS

Fully owned pipeline

#	Target	Indications	Modality	Discovery	Preclinical*	IND Filing	Phase IA / IB
CT-01	GSPT1, NEK7, SALL4	Hepatocellular carcinoma, Lung cancer, NET tumours	MG				
CT-02	NEK7	Autoimmunity, CNS, Metabolism, Oncology	MG				
CT-03	MCL-1	Liquid & solid tumours	BID				
CT-05	PKCϴ	Autoimmunity, Oncology, Transplantation, Metabolism	BID				
CT-09	IDP** target	CRC, Haemato-oncology, I/O	MG				
	New E3 ligase degraders	Autoimmunity, Cancer	MG BID				

Preclinical stage include IND-enabling studies, **BID – Bi-functional Degrader; **MG** – Molecular Glue, ** - IDP – Intrinsically Disordered Protein*

Assumed stage at the end of 2025

Captor Therapeutics®

CT-01: Multi-target GSPT1, NEK7 & SALL4 degrader



GSPT1 degradation leads to an Integrated Stress Response and induction of apoptosis in HCC cells

SALL4 is expressed in fetal liver, silenced in adults, but often re-expressed in HCC and correlates with poor prognosis

NEK7 degradation leads to reduction of IL-1β production – a well-establish pro-carcinogenic factor. Reduction of IL-1β levels enables activation of the immune response

CPT-6281 is a pro-drug activated by an enzyme present at high levels in the liver, lungs and certain gastrointestinal tumours

A unique degradation profile combined with target tissue pro-drug activation for liver, lung and neuroendocrine cancers

Captor Therapeutics®

Recent achievements

- Completion of GLP-tox in life phase with no gross findings
    - Awaiting histopathology and full report
- Demonstrated combination with everolimus potentiates degradation of target proteins
- Status:
    - Production of a GMP-batch and drug product for clinical studies ongoing
    - IB in preparation
    - Finalising appointment of CRO to supervise clinical study

Captor Therapeutics®

CT-02: Vast market potential for inflammasome modulators



Captor Therapeutics®

Lead compounds show excellent selectivity profile / safety profile



All the lead compounds demonstrate high safety profile in CEREP panel

Captor Therapeutics®

CT-03: MCL-1 – a critical pathway of cancer resistance



MCL-1 is one of the most amplified proteins in cancer

A critical resistance mechanism in haematological and solid tumours

Degradation of inhibition of MCL-1 protein directly attenuates tumours in vivo as monotherapy & sensitizes tumors for other therapies

Adequate ablation of MCL-1 requires rapid and sustained action & high target coverage

Use of inhibitors causes accumulation of MCL1 in cancer cells

Degraders have a different mode of action, without accumulation of MCL1

Degradation of ~70% of MCL-1 induces apoptosis, while inhibitors require nearly 100% of target coverage. This, together, with optimized clearance expands the therapeutic window from the perspective of cardiotoxicity

Captor Therapeutics®

Milestones

- Two MCL-1 bifunctional degraders have been developed with high potency (DC_{50}) of <1 nM and 100 nM
- Both compounds potently inhibit tumor growth *in vivo*
- Both compounds do not affect NHP troponin-I (a marker of heart muscle damage) levels at doses higher than the effective doses
- ~1 kg of a first compound was produced and is a single synthesis step from the second compound
- Candidate selection planned for Q4 2023

Captor Therapeutics®

CT-05: PKC$_\Theta$ an inadequately drugged high value target





Captor Therapeutics®

Best-in-class selectivity

Inhibitor shows significant effects on non-immune cells
Degrader has no effect in non-immune cells



Compound	IC_{50}	I_{max}	DC_{50}
Lead compound	55 nM	82 %	29 nM
ABS-911	98 nM	99 %	N/A

Excellent selectivity against a large number of kinases

KinomeScan results
TREE*spot*™ Interaction Map
panel of ca. 450 kinases



Captor Therapeutics®

Optigrade™ discovery platform – importance of structure & chemistry



Optigrade™ – addressing Molecular Glues, Bifunctional Degraders and novel Ubiquitin E3 Ligases

Leading chemistry expertise in creating "activated" degraders to increase intracellular potency

Captor Therapeutics®

Optigrade™ discovery platform

Molecular Glue

CT-09



New E3 Ligases

- **First-in-class degrader** of an Intrinsically Disordered Protein (IDP)
- **High commercial potential** in CRC, hematological cancers and immuno-oncology
- Disordered architecture **precludes of development of classical inhibitors**

To date we have:

1. Identified hits
2. Solved X-ray structure of the target in complex with E3 ligase and a hit compound

- Demonstrated **first degradation** of a target protein using the **novel ligase KLHDC2**
- Recently demonstrated **degradation of 2 additional new kinases with KLHDC2**
- **Established a production workflow** for the Kelch family of novel ligases

Captor Therapeutics®

FINANCIALS AND PLANS FOR THE FUTURE

Strong balance sheet and cash position

Consolidated statement of financial position (PLN, M)



Cash position



Available funding secured (PLN M; as of June 30, 2023):

Total : PLN 137,4 M

- PLN 58,7 cash, short-term bonds
- PLN 78,7 available grants (NCBR; ABM)

R&D costs in H1 2023:

Total : PLN 38,2 M

Cash outflow in H1 2023:

Total : PLN 32,2 M

Captor Therapeutics®

Next steps

2023

- **CT-01**: Submit Clinical Trial Authorisation application
- **CT-02** and **CT-05**: *In vivo* proof of concept in autoimmunity
- In cell degradation of target with novel E3 ligase-based degrader

2024

- **CT-03**: Submit Clinical Trial Authorisation application
- **CT-01**: Clinical readouts: safety, pharmacology, & mechanism
- First degrader of a new target based on novel E3 ligase
- New partnering in immunology

Captor Therapeutics®

Q&A SESSION

Captor Therapeutics®

Captor Therapeutics S.A
ul. Duńska 11
54-427 Wrocław, Poland

Captor Therapeutics GmbH
Hegenheimermattweg 167A
4123 Allschwil, Switzerland

Contact: relacje.inwestorskie@captortherapeutics.com

Projects co-financed by the European Regional Development Fund:

Discovery and development of a new clinical drug candidate for the eradication of cancer stem cell in the treatment of hepatocellular carcinoma, through degradation of oncofetal transcription factor
(POIR.01.01.01-00-0740/19-00)

Discovery and development of non-toxic ligase ligands and their application in the treatment of autoimmunological diseases
(POIR.01.01.01-00-0741/19-00)

Inducing apoptosis with small molecules as therapeutic intervention in multiple severe malignancies
(POIR.01.01.01-00-0956/17-01)

Application of targeted protein degradation technology in the treatment of psoriasis and rheumatoid arthritis
(POIR.01.02.00-00-0079/18-00)

Development of an integrated technology platform in the field of targeted protein degradation and its implementation to the pharmaceutical market
(POIR.01.01.01-00-0931/19-00)

European Funds Smart Growth | Republic of Poland | The National Centre for Research and Development | European Union European Regional Development Fund

Project co-financed by the state budget from the Medical Research Agency:

Design and clinical development of a first-in-class small-molecule drug candidate for the treatment of colorectal cancer based on the stimulation of immune cells to increase anti-cancer activity through induced protein degradation
(2022/ABM/06/00001 - 00)

MEDICAL RESEARCH AGENCY